| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Roflumilast | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | | Roflumilast | hsa00062 | Fatty acid elongation | 3.94E-02 | 1 | Q9H5J4 | ELOVL6 | More | | | Roflumilast | hsa00190 | Oxidative phosphorylation | 1.07E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Roflumilast | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Roflumilast | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | | Roflumilast | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Roflumilast | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Roflumilast | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Roflumilast | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | | Roflumilast | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | | Roflumilast | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.13E-03 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | | | Roflumilast | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | | Roflumilast | hsa01212 | Fatty acid metabolism | 2.13E-03 | 2 | Q9H5J4, P22307 | ELOVL6, SCP2 | More | | | Roflumilast | hsa03040 | Spliceosome | 1.54E-06 | 16 | Q14562, O43143, O60508, P08579, P26368, O75940, O75494, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, SMNDC1, FUSIP1, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | | Roflumilast | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | | Roflumilast | hsa04014 | Ras signaling pathway | 1.30E-03 | 12 | P42338, P20827, Q9NRA1, P49767, Q13009, P17252, Q7LDG7, P0DP23, P62873, P63218, P50151, P19174 | PIK3CB, EFNA1, PDGFC, VEGFC, TIAM1, PRKCA, RASGRP2, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | | Roflumilast | hsa04015 | Rap1 signaling pathway | 2.42E-03 | 11 | P20827, Q9NRA1, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P0DP23, P17252, P19174 | EFNA1, PDGFC, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, CALM1, PRKCA, PLCG1 | More | | | Roflumilast | hsa04020 | Calcium signaling pathway | 2.01E-02 | 6 | P17252, P19174, P0DP23, P20020, Q9NRA1, P49767 | PRKCA, PLCG1, CALM1, ATP2B1, PDGFC, VEGFC | More | | | Roflumilast | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | | | Roflumilast | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | | Roflumilast | hsa04062 | Chemokine signaling pathway | 5.65E-04 | 14 | P25024, P25025, P09341, P19875, P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | | Roflumilast | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | | | Roflumilast | hsa04070 | Phosphatidylinositol signaling system | 4.40E-02 | 4 | P19174, P0DP23, P23743, P17252 | PLCG1, CALM1, DGKA, PRKCA | More | | | Roflumilast | hsa04072 | Phospholipase D signaling pathway | 5.17E-03 | 7 | P42338, Q92529, P43657, P25024, P25025, P19174, Q14344 | PIK3CB, SHC3, P2RY5, CXCR1, CXCR2, PLCG1, GNA13 | More | | | Roflumilast | hsa04145 | Phagosome | 4.68E-02 | 5 | Q15080, P14598, Q13509, P68371, Q13488 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1 | More | | | Roflumilast | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | | Roflumilast | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | | Roflumilast | hsa04217 | Necroptosis | 1.36E-02 | 7 | P01568, P42224, P08238, Q6FI13, Q93077, O43633, Q08752 | IFNA21, STAT1, HSP90AB1, H2AC18; H2AC19, HIST1H2AC, CHMP2A, PPID | More | | | Roflumilast | hsa04360 | Axon guidance | 3.14E-03 | 7 | P16333, P20827, O95631, P17252, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PRKCA, PIK3CB, FES, PLCG1 | More | | | Roflumilast | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | | Roflumilast | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | | Roflumilast | hsa04390 | Hippo signaling pathway | 4.35E-02 | 2 | P63261, O15105 | ACTG1, SMAD7 | More | | | Roflumilast | hsa04530 | Tight junction | 4.35E-02 | 2 | P63261, Q92974 | ACTG1, ARHGEF2 | More | | | Roflumilast | hsa04540 | Gap junction | 1.67E-02 | 4 | P17252, Q13509, P68371, Q9NRA1 | PRKCA, TUBB3, TUBB2C, PDGFC | More | | | Roflumilast | hsa04623 | Cytosolic DNA-sensing pathway | 3.29E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | | Roflumilast | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | | | Roflumilast | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | | Roflumilast | hsa04650 | Natural killer cell mediated cytotoxicity | 2.48E-03 | 8 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3 | More | | | Roflumilast | hsa04657 | IL-17 signaling pathway | 1.16E-03 | 10 | P25963, P08238, O00463, Q07955, Q16539, P49841, P14780, P04141, P01375, P06702 | NFKBIA, HSP90AB1, TRAF5, SFRS1, MAPK14, GSK3B, MMP9, CSF2, TNF, S100A9 | More | | | Roflumilast | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | | Roflumilast | hsa04659 | Th17 cell differentiation | 9.05E-05 | 11 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P84022, Q13485, P08238, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, SMAD3, SMAD4, HSP90AB1, CD3E, CD247 | More | | | Roflumilast | hsa04660 | T cell receptor signaling pathway | 4.48E-04 | 13 | P04141, P25963, Q04759, P42338, P10747, P19174, P16333, P07766, P20963, P01732, Q13191, P06239, P29350 | CSF2, NFKBIA, PRKCQ, PIK3CB, CD28, PLCG1, NCK1, CD3E, CD247, CD8A, CBLB, LCK, PTPN6 | More | | | Roflumilast | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Roflumilast | hsa04664 | Fc epsilon RI signaling pathway | 2.40E-03 | 7 | P01375, Q16539, P42338, Q9UQC2, P07948, P19174, P09917 | TNF, MAPK14, PIK3CB, GAB2, LYN, PLCG1, ALOX5 | More | | | Roflumilast | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | | | Roflumilast | hsa04713 | Circadian entrainment | 3.32E-02 | 4 | P0DP23, P17252, P62873, O15055 | CALM1, PRKCA, GNB1, PER2 | More | | | Roflumilast | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | | | Roflumilast | hsa04744 | Phototransduction | 1.18E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | | Roflumilast | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | | Roflumilast | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | | Roflumilast | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.52E-03 | 8 | P84022, Q13485, P42224, P42338, Q12778, P49767, P17252, P19174 | SMAD3, SMAD4, STAT1, PIK3CB, FOXO1, VEGFC, PRKCA, PLCG1 | More | | | Roflumilast | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | | | Roflumilast | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | | Roflumilast | hsa05012 | Parkinson disease | 3.12E-02 | 6 | Q16718, O14521, P19174, P0DP23, Q13509, P68371 | NDUFA5, SDHD, PLCG1, CALM1, TUBB3, TUBB2C | More | | | Roflumilast | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.29E-02 | 9 | Q13509, P68371, Q16718, O14521, Q13561, P19174, P17252, Q08752, P0DP23 | TUBB3, TUBB2C, NDUFA5, SDHD, DCTN2, PLCG1, PRKCA, PPID, CALM1 | More | | | Roflumilast | hsa05110 | Vibrio cholerae infection | 1.98E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | | Roflumilast | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | | Roflumilast | hsa05132 | Salmonella infection | 1.70E-02 | 8 | P25963, P08238, P04406, O75369, Q13561, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, GAPDH, FLNB, DCTN2, TUBB3, TUBB2C, VPS41 | More | | | Roflumilast | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | | Roflumilast | hsa05140 | Leishmaniasis | 1.72E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | | | Roflumilast | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | | | Roflumilast | hsa05163 | Human cytomegalovirus infection | 2.80E-02 | 6 | P01375, P49841, P14778, P25025, Q16539, O00463 | TNF, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | | Roflumilast | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 5.71E-03 | 8 | P01568, P42224, P25963, P40189, P62873, P19174, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, IL6ST, GNB1, PLCG1, CSF2, CALM1 | More | | | Roflumilast | hsa05168 | Herpes simplex virus 1 infection | 4.15E-03 | 12 | P25963, P01568, Q9GZY0, P42224, Q07955, Q01130, Q13243, Q13398, Q03923, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, NXF2; NXF2B, STAT1, SFRS1, SFRS2, SFRS5, ZNF211, ZNF85, ZNF140, ZNF189, ZNF212 | More | | | Roflumilast | hsa05171 | Coronavirus disease - COVID-19 | 1.36E-02 | 7 | P25963, P42224, P01568, P40189, P04141, P19174, P17252 | NFKBIA, STAT1, IFNA21, IL6ST, CSF2, PLCG1, PRKCA | More | | | Roflumilast | hsa05200 | Pathways in cancer | 5.58E-04 | 26 | Q13751, P42338, P08238, P42224, P25963, P19174, P17252, P43246, P84022, Q13485, Q13547, P14923, P30281, P49767, Q12778, P43657, P62873, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P01568, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, VEGFC, FOXO1, P2RY5, GNB1, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.826 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.912 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.739 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.739 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P17252 | PRKCA | Protein kinase C alpha type | 0.832 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.768 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P14923 | JUP | Junction plakoglobin | 0.735 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P49767 | VEGFC | Vascular endothelial growth factor C | 0.761 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Q12778 | FOXO1 | Forkhead box protein O1 | 0.753 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.833 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.713 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P0DP23 | CALM1 | Calmodulin-1 | -0.761 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P01568 | IFNA21 | Interferon alpha-21 | 0.729 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P40189 | IL6ST | Interleukin-6 receptor subunit beta | -0.746 |
| | Roflumilast | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | | Roflumilast | hsa05214 | Glioma | 1.09E-02 | 4 | P0DP23, P17252, P19174, O75293 | CALM1, PRKCA, PLCG1, GADD45B | More | | | Roflumilast | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | | Roflumilast | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | | | Roflumilast | hsa05231 | Choline metabolism in cancer | 2.25E-03 | 5 | Q9NRA1, Q9Y259, P19174, P23743, P17252 | PDGFC, CHKB, PLCG1, DGKA, PRKCA | More | | | Roflumilast | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 7.13E-04 | 10 | P25963, P42338, P19174, P07766, P20963, P06239, P29350, P42224, P10747, Q04759 | NFKBIA, PIK3CB, PLCG1, CD3E, CD247, LCK, PTPN6, STAT1, CD28, PRKCQ | More | | | Roflumilast | hsa05415 | Diabetic cardiomyopathy | 1.20E-02 | 6 | P17252, P14598, Q15080, Q16718, O14521, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, GAPDH | More | | | Roflumilast | hsa05418 | Fluid shear stress and atherosclerosis | 1.08E-03 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |
|
